Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.

doi:10.1016/j.lungcan.2021.06.018

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2021

Mondaca Sebastian, Lebow Emily S, Namakydoust Azadeh, Razavi Pedram, Reis-Filho Jorge S, Shen Ronglai, Offin Michael, Tu Hai-Yan, Murciano-Goroff Yonina, Xu Chongrui, Makhnin Alex, Martinez Andres, Pavlakis Nick, Clarke Stephen, Itchins Malinda, Lee Adrian, Rimner Andreas, Gomez Daniel, Rocco Gaetano, Chaft Jamie E, Riely Gregory J, Rudin Charles M, Jones David R, Li Mark, Shaffer Tristan, Hosseini Seyed Ali, Bertucci Caterina, Lim Lee P, Drilon Alexander, Berger Michael F, Benayed Ryma, Arcila Maria E, Isbell James M, Li Bob T

Abstract excerpt

OBJECTIVES: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) can detect ALK fusions, though data on clinical utility of this technology in the real world is limited. MATERIALS AND METHODS: Patients with lung cancer without known oncogenic drivers or who had acquired resistance to therapy (n = 736) underwent prospective plasma ctDNA NGS. A subset of this cohort (n = 497) also...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryldialkylphosphatase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to High-Throughput Nucleotide Sequencing

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 34311346
DOI: 10.1016/j.lungcan.2021.06.018
PMCID: PMC8594131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.PMID 34311346Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.Semantic proximity Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer TypesSemantic proximity Read ↗

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.Semantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysisSemantic proximity Read ↗

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancerSemantic proximity Read ↗

Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A Performance Comparison of Commonly Used Assays to Detect RET FusionsSemantic proximity Read ↗

Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.